Skip to content

National Lymphangioleiomyomatosis Registry, France

National Lymphangioleiomyomatosis Registry, France

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01484236
Acronym
RE-LAM-CE
Enrollment
200
Registered
2011-12-02
Start date
2012-01-01
Completion date
2028-12-01
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphangioleiomyomatosis

Keywords

Lymphangioleiomyomatosis

Brief summary

RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis. Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.

Detailed description

Lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. Few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression. Several sources of information will be used in order to increase completeness. The registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Competence Centers for rare lung diseases in France. Data will be collected by a research assistant, and the study will be coordinated by the Pole IMER - Department of Public health and Epidemiology of HCL (Lyon Hospitals). This study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. This study will provide the first detailed epidemiological information on Lymphangioleiomyomatosis, will assess the management of this rare disease within the French National Plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials

Interventions

None listed

Sponsors

Vincent COTTIN
Lead SponsorOTHER
Hospices Civils de Lyon
CollaboratorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with sporadic lymphangioleiomyomatosis or associated with Tuberous sclerosis. * patients diagnosed or hospitalized or seen in consultation since 01/01/2008

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Number of cases4 yearsDetermine incidence and prevalence of lymphangioleiomyomatosis.

Secondary

MeasureTime frameDescription
localisation of cases4 yearsEstimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Centers of excellence for rare lung diseases in France (coverage rate of centers)
Progression-free survival4 yearsDetermine the frequency of the various forms with mild to moderate or severe, and rapid or slow evolution.

Countries

France

Contacts

CONTACTVincent Cottin, MD
33-427-857-700
CONTACTRaphaële Guelminger, CRA
33-472-357-074
PRINCIPAL_INVESTIGATORVincent Cottin, MD

Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires, HCL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026